

























![]()
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2026 Earnings Call May 12, 2026 8:00 AM EDT
Company Participants
Alex Braun - VP & Head of Investor Relations
Daniel O'Connell - CEO & Director
Matt Zuga - CFO & Chief Business Officer
James Doherty - President & Chief Development Officer
Eric Siemers - Chief Medical Officer
Conference Call Participants
Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division
Mary Kate Davis
Jason Zemansky - BofA Securities, Research Division
Jimmy Kim
Dev Prasad - Lucid Capital Markets, LLC, Research Division
Presentation
Operator
Good day, and thank you for standing by. Welcome to the Acumen Pharma First Quarter 2026 Conference Call and Webcast. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Alex Braun, Head of Investor Relations. Please go ahead.
Alex Braun
VP & Head of Investor Relations
Thanks, Didi. Good morning, and welcome to the Acumen conference call to discuss our business update and financial results for the quarter ended March 31, 2026. With me today are Dan O'Connell, our Chief Executive Officer; and Matt Zuga, our CFO and Chief Business Officer.
They will have brief prepared remarks, and then we'll open the call for questions. Joining for the Q&A session, we also have Dr. Jim Doherty, our President and Chief Development Officer; and Dr. Eric Siemers, our Chief Medical Officer. Before we begin, we encourage listeners to go to the Investors section of the Acumen website to find our press release issued this morning that we'll discuss today.
Please note that during today's conference call, we may make forward-looking statements within the meaning of the federal securities laws. Including statements concerning our financial outlook and expected business plans. Please see Slide 2 of our corporate presentation, our press release issued this morning and our most recent
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。